article
NIR In-Depth Focus 2015
In this NIR In-Depth Focus: Challenges with NIR reflectance measurements of solid pharmaceuticals, Application of NIR spectroscopy in linking velocity profiles of a binary granular system...
List view / Grid view
Bristol-Myers Squibb Company
news
FDA accepts supplemental Biological License Application for Opdivo
2 September 2015 | By Victoria White
The FDA has accepted for filing and review the supplemental Biological licence Application for Opdivo for the treatment of patients with non-squamous NSCLC...
news
BMS gets exclusive rights to acquire Promedior
2 September 2015 | By Victoria White
As well as granting exclusive rights to acquire Promedior, the agreement grants Bristol-Myers Squibb worldwide rights to Promedior's lead asset PRM-151.
news
FDA grants priority review for Empliciti Biologics License Application
2 September 2015 | By Victoria White
The FDA has accepted for priority review the BLA for Empliciti (elotuzumab) for the treatment of multiple myeloma as combination therapy...
news
Phase 1/2 trial of Mogamulizumab and Opdivo in advanced solid tumours announced
30 July 2015 | By Victoria White
Kyowa Hakko Kirin and Bristol-Myers Squibb are to conduct a Phase 1/2 combination study with mogamulizumab and Opdivo in advanced solid tumours...
news
EMA grants accelerated assessment of MAA for Empliciti
27 July 2015 | By Victoria White
The EMA validated for review the Marketing Authorisation Application (MAA) for Empliciti for the treatment of multiple myeloma...
news
FDA approves Daklinza for the treatment of HCV genotype 3
27 July 2015 | By Victoria White
Daklinza has been approved by the US FDA, marking the first time patients with chronic HCV genotype 3 have a 12-week, once-daily, all-oral treatment option...
news
EMA validates two Opdivo indication extension applications
23 July 2015 | By Victoria White
The EMA has validated two type II variation applications which seek to extend the indication of Opdivo in non-squamous NSCLC and advanced melanoma...
news
HIV-1 maturation inhibitor BMS-955176 demonstrates positive new Phase IIa results
22 July 2015 | By Victoria White
Bristol-Myers Squibb has announced additional Phase IIa data for BMS-955176, a novel investigational agent designed to prevent the maturation of HIV-1...
news
FDA grants Breakthrough Therapy Designation to Bristol-Myers Squibb’s BMS-663068
21 July 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation to BMS-663068 for the treatment of HIV-1 infection in heavily treatment-experienced adult patients...
news
EC approves nivolumab for patients with previously-treated advanced squamous non-small cell lung cancer
21 July 2015 | By Victoria White
The EC has approved nivolumab for the treatment of locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy...
news
CheckMate -025, a Phase III Opdivo renal cell cancer trial, stopped early
20 July 2015 | By Victoria White
The CheckMate -025 study evaluating Opdivo versus everolimus in patients with advanced or metastatic RCC has been stopped early as it met its endpoint...
news
EC approves Evotaz for the treatment of HIV-1 infection in adults
16 July 2015 | By Victoria White
The EC has approved Evotaz tablets in combination with other antiretroviral agents for the treatment of HIV-1 infected adults...
news
Bristol-Myers Squibb will win big with melanoma combination immunotherapy
23 June 2015 | By Victoria White
Data presented at ASCO 2015 suggests that the Opdivo/Yervoy combination of immunotherapies to treat metastatic melanoma will shape the therapeutic landscape...
news
Results of Phase 3 study of andexanet alfa presented at ISTH 2015
22 June 2015 | By Victoria White
Full results from the second part of a Phase 3 trial evaluating the safety and efficacy of andexanet alfa as a reversal agent of Eliquis have been announced...
